文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移速度:预测 upfront SRS 后远处脑失败患者总生存与免于全脑放疗的新预后指标

Brain Metastasis Velocity: A Novel Prognostic Metric Predictive of Overall Survival and Freedom From Whole-Brain Radiation Therapy After Distant Brain Failure Following Upfront Radiosurgery Alone.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-26

研究提出脑转移速度(BMV)这一新指标,定义为自首次 SRS 以来每年新发脑转移的累积数量。737 例接受 upfront SRS 未行 WBRT 的患者中,286 例发生至少一次远处脑失败(DBF)。BMV 越低,DBF 后总生存(OS)越好,低、中、高风险组中位 OS 分别为 12.4、8.2、4.3 个月,且低 BMV 与更低的挽救 WBRT 率和神经性死亡率相关。

要点

  • BMV 定义为自首次 SRS 起每年新发脑转移的累积数量,分低(<4)、中(4–13)、高(>13)三组。
  • BMV 是 DBF 后 OS 的主要预测因素,高风险组 HR 为 2.75(95%CI 1.94–3.89,P<.0001)。
  • 低 BMV 与更低的挽救 WBRT 率(P=.02)和神经性死亡率(P=.008)相关。

核心结论

  • BMV 是与 upfront SRS 后首次 DBF 患者 OS、神经性死亡及挽救 WBRT 需求相关的新指标。

研究设计与样本

  • 单中心回顾性分析,737 例接受 upfront SRS 未行 WBRT 的患者中 286 例发生至少一次 DBF,按 BMV 分为低、中、高风险组。

主要发现

  • 低、中、高 BMV 组 DBF 后中位 OS 分别为 12.4 个月(95%CI 10.4–16.9)、8.2 个月(95%CI 5.0–9.7)和 4.3 个月(95%CI 2.6–6.7),log-rank P<.0001。
  • 多因素分析中 BMV 仍为 OS 的主要预测因素,高风险组 HR 2.75(95%CI 1.94–3.89,P<.0001),中风险组 HR 1.65(95%CI 1.18–2.30,P<.004)。
  • 低 BMV 与更低的挽救 WBRT 率(P=.02)和神经性死亡率(P=.008)相关。
  • 预测更高 BMV 的因素包括初始脑转移≥2 个(P=.004)和黑色素瘤组织学(P=.008)。

关键数值与推荐

  • BMV 低风险组为每年 <4 个新发脑转移,中风险组为 4–13 个,高风险组为 >13 个。

临床怎么用

  • 对 upfront SRS 后发生 DBF 的患者,可根据 BMV 分层评估预后,低 BMV 者 OS 更长且挽救 WBRT 需求更低。
  • 初始脑转移≥2 个或黑色素瘤组织学患者可能 BMV 更高,需加强随访与分层管理。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prior statistical models attempted to identify risk factors for time to distant brain failure (DBF) or time to salvage whole-brain radiation therapy (WBRT) to predict the benefit of early WBRT versus stereotactic radiosurgery (SRS) alone. We introduce a novel clinical metric, brain metastasis velocity (BMV), for predicting clinical outcomes after initial DBF following upfront SRS alone. METHODS AND MATERIALS: BMV was defined as the cumulative number of new brain metastases that developed over time since first SRS in years. Patients were classified by BMV into low-, intermediate-, and high-risk groups, consisting of <4, 4 to 13, and >13 new metastases per year, respectively. Histology, number of metastases at the time of first SRS, and systemic disease status were assessed for effect on BMV. RESULTS: Of 737 patients treated at our institution with upfront SRS without WBRT, 286 had ≥1 DBF event. A lower BMV predicted for improved overall survival (OS) following initial DBF (log-rank P<.0001). Median OS for the low, intermediate, and high BMV groups was 12.4 months (95% confidence interval [CI], 10.4-16.9 months), 8.2 months (95% CI, 5.0-9.7 months), and 4.3 months (95% CI, 2.6-6.7 months), respectively. Multivariate analysis showed that BMV remained the dominant predictor of OS, with a hazard ratio of 2.75 for the high BMV group (95% CI, 1.94-3.89; P<.0001) and a hazard ratio of 1.65 for the intermediate BMV group (95% CI, 1.18-2.30; P<.004). A lower BMV was associated with decreased rates of salvage WBRT (P=.02) and neurologic death (P=.008). Factors predictive for a higher BMV included ≥2 initial brain metastases (P=.004) and melanoma histology (P=.008). CONCLUSIONS: BMV is a novel metric associated with OS, neurologic death, and need for salvage WBRT after initial DBF following upfront SRS alone.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Farris M, McTyre ER, Cramer CK, et al. Brain Metastasis Velocity: A Novel Prognostic Metric Predictive of Overall Survival and Freedom From Whole-Brain Radiation Therapy After Distant Brain Failure Following Upfront Radiosurgery Alone. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586952. doi:10.1016/j.ijrobp.2017.01.201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。